Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma.
Nan XiaoXiaodong ZhuKangshuai LiYifan ChenXuefeng LiuBin XuMing LeiJiejie XuHui-Chuan SunPublished in: Experimental hematology & oncology (2021)
Siglec-10hi TAMs are associated with immune suppression in the TME, and indicate poor prognosis in patients with HCC. Targeting Siglec-10hi TAMs may serve as a promising immunotherapy approach for HCC.